135 related articles for article (PubMed ID: 36410418)
1. Discovery of anticancer agents with c-Met inhibitory potential by virtual and experimental screening of a chemical library.
Mortazavi M; Raufi E; Damghani T; Khoshneviszadeh M; Edraki N; Eskandari M; Giovannetti E; Peters GJ; Pirhadi S; Firuzi O
Eur J Pharmacol; 2023 Jan; 938():175395. PubMed ID: 36410418
[TBL] [Abstract][Full Text] [Related]
2. Imidazopyridine hydrazone derivatives exert antiproliferative effect on lung and pancreatic cancer cells and potentially inhibit receptor tyrosine kinases including c-Met.
Damghani T; Moosavi F; Khoshneviszadeh M; Mortazavi M; Pirhadi S; Kayani Z; Saso L; Edraki N; Firuzi O
Sci Rep; 2021 Feb; 11(1):3644. PubMed ID: 33574356
[TBL] [Abstract][Full Text] [Related]
3. Antiproliferative effect, alteration of cancer cell cycle progression and potential MET kinase inhibition induced by 3,4-dihydropyrimidin-2(1H)-one C5 amide derivatives.
Moosavi F; Ebadi A; Mohabbati M; Damghani T; Mortazavi M; Miri R; Firuzi O
Eur J Pharmacol; 2021 Mar; 894():173850. PubMed ID: 33428899
[TBL] [Abstract][Full Text] [Related]
4. Novel quinazoline-1,2,3-triazole hybrids with anticancer and MET kinase targeting properties.
Mortazavi M; Eskandari M; Moosavi F; Damghani T; Khoshneviszadeh M; Pirhadi S; Saso L; Edraki N; Firuzi O
Sci Rep; 2023 Sep; 13(1):14685. PubMed ID: 37673888
[TBL] [Abstract][Full Text] [Related]
5. Virtual Screening Guided Design, Synthesis and Bioactivity Study of Benzisoselenazolones (BISAs) on Inhibition of c-Met and Its Downstream Signalling Pathways.
Zhang S; Song Q; Wang X; Wei Z; Yu R; Wang X; Jiang T
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31137515
[TBL] [Abstract][Full Text] [Related]
6. ImmunoPET Predicts Response to Met-targeted Radioligand Therapy in Models of Pancreatic Cancer Resistant to Met Kinase Inhibitors.
Escorcia FE; Houghton JL; Abdel-Atti D; Pereira PR; Cho A; Gutsche NT; Baidoo KE; Lewis JS
Theranostics; 2020; 10(1):151-165. PubMed ID: 31903112
[No Abstract] [Full Text] [Related]
7. Synthesis and biological evaluation of some novel thiobenzimidazole derivatives as anti-renal cancer agents through inhibition of c-MET kinase.
Ibrahim HS; Albakri ME; Mahmoud WR; Allam HA; Reda AM; Abdel-Aziz HA
Bioorg Chem; 2019 Apr; 85():337-348. PubMed ID: 30658233
[TBL] [Abstract][Full Text] [Related]
8. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers.
Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M
Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234
[TBL] [Abstract][Full Text] [Related]
9. Design, Synthesis and Biological Evaluation of Novel 4-phenoxypyridine Derivatives Containing Semicarbazones Moiety as Potential c-Met Kinase Inhibitors.
Li J; Li J; Zhang J; Shi J; Ding S; Liu Y; Chen Y; Liu J
Anticancer Agents Med Chem; 2020; 20(5):559-570. PubMed ID: 31893997
[TBL] [Abstract][Full Text] [Related]
10. Phytochemicals, withaferin A and carnosol, overcome pancreatic cancer stem cells as c-Met inhibitors.
Aliebrahimi S; Kouhsari SM; Arab SS; Shadboorestan A; Ostad SN
Biomed Pharmacother; 2018 Oct; 106():1527-1536. PubMed ID: 30119228
[TBL] [Abstract][Full Text] [Related]
11. Study of the anticancer effect of new quinazolinone hydrazine derivatives as receptor tyrosine kinase inhibitors.
Mortazavi M; Divar M; Damghani T; Moosavi F; Saso L; Pirhadi S; Khoshneviszadeh M; Edraki N; Firuzi O
Front Chem; 2022; 10():969559. PubMed ID: 36465863
[TBL] [Abstract][Full Text] [Related]
12. KRas4B-PDE6δ complex stabilization by small molecules obtained by virtual screening affects Ras signaling in pancreatic cancer.
Casique-Aguirre D; Briseño-Díaz P; García-Gutiérrez P; la Rosa CHG; Quintero-Barceinas RS; Rojo-Domínguez A; Vergara I; Medina LA; Correa-Basurto J; Bello M; Hernández-Rivas R; Del RocioThompson-Bonilla M; Vargas M
BMC Cancer; 2018 Dec; 18(1):1299. PubMed ID: 30594165
[TBL] [Abstract][Full Text] [Related]
13. Molecular Docking and In Vitro Anticancer Screening of Synthesized Arylthiazole linked 2H-indol-2-one Derivatives as VEGFR-2 Kinase Inhibitors.
Shalmali N; Bawa S; Ali MR; Kalra S; Kumar R; Zeya B; Rizvi MA; Partap S; Husain A
Anticancer Agents Med Chem; 2022; 22(11):2166-2180. PubMed ID: 34792005
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of novel 4-phenoxypyridine based 3-oxo-3,4-dihydroquinoxaline-2-carboxamide derivatives as potential c-Met kinase inhibitors.
Wang Z; Shi J; Zhu X; Zhao W; Gong Y; Hao X; Hou Y; Liu Y; Ding S; Liu J; Chen Y
Bioorg Chem; 2020 Dec; 105():104371. PubMed ID: 33075664
[TBL] [Abstract][Full Text] [Related]
15. 1,2,4-Oxadiazole Topsentin Analogs with Antiproliferative Activity against Pancreatic Cancer Cells, Targeting GSK3β Kinase.
Carbone D; Parrino B; Cascioferro S; Pecoraro C; Giovannetti E; Di Sarno V; Musella S; Auriemma G; Cirrincione G; Diana P
ChemMedChem; 2021 Feb; 16(3):537-554. PubMed ID: 33141472
[TBL] [Abstract][Full Text] [Related]
16. Structure-based discovery of novel 4-(2-fluorophenoxy)quinoline derivatives as c-Met inhibitors using isocyanide-involved multicomponent reactions.
Nan X; Li HJ; Fang SB; Li QY; Wu YC
Eur J Med Chem; 2020 May; 193():112241. PubMed ID: 32200199
[TBL] [Abstract][Full Text] [Related]
17. A New Oxadiazole-Based Topsentin Derivative Modulates Cyclin-Dependent Kinase 1 Expression and Exerts Cytotoxic Effects on Pancreatic Cancer Cells.
Pecoraro C; Parrino B; Cascioferro S; Puerta A; Avan A; Peters GJ; Diana P; Giovannetti E; Carbone D
Molecules; 2021 Dec; 27(1):. PubMed ID: 35011251
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and molecular modeling studies of new series of antitumor 1,2,4-triazines with potential c-Met kinase inhibitory activity.
El-Wakil MH; Ashour HM; Saudi MN; Hassan AM; Labouta IM
Bioorg Chem; 2018 Feb; 76():154-165. PubMed ID: 29175587
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors.
Wang LX; Liu X; Xu S; Tang Q; Duan Y; Xiao Z; Zhi J; Jiang L; Zheng P; Zhu W
Eur J Med Chem; 2017 Dec; 141():538-551. PubMed ID: 29107421
[TBL] [Abstract][Full Text] [Related]
20. Target identification, lead optimization and antitumor evaluation of some new 1,2,4-triazines as c-Met kinase inhibitors.
El-Wakil MH; Ashour HM; Saudi MN; Hassan AM; Labouta IM
Bioorg Chem; 2017 Aug; 73():154-169. PubMed ID: 28715754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
